Outlook on the Advanced Therapy Medicinal Products Global Market to 2027 - Featuring F. Hoffmann-La Roche, Bluebird Bio, UniQure and Kolon TissueGene Among Others - ResearchAndMarkets.com

DUBLIN--()--The "Advanced Therapy Medicinal Products (ATMPs) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The advanced therapy medicinal products (ATMPs) market is projected to register a CAGR of 13% during the forecast period.

Companies Mentioned

  • Novartis AG
  • Gilead Sciences, Inc.
  • JCR Pharmaceuticals Co. Ltd
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Bluebird Bio Inc.
  • UniQure NV
  • Kolon TissueGene Inc.
  • Vericel Corporation

Key Market Trends

The Tissue-Engineered Product Segment is Expected to Hold a Major Market Share in the Advanced Therapy Medicinal Products (ATMPs) Market

The estimated large share of the tissue-engineered product is the presence of a relatively large number of commercially approved products under this segment. Furthermore, the increasing application of tissue-engineered products in treatment procedures that require functional restoration of any diseased or injured part of the body is driving the segment growth.

Furthermore, market players continue to undertake various market strategies to boost the adoption of their products. For instance, in January 2021, Vericel Corporation announced the expansion of the medical coverage policy for MACI by United Healthcare. The expansion includes coverage for patients with multiple cartilage defects in the knee and symptomatic full-thickness cartilage defects in the patella. Such initiatives by the company are driving the segment's growth to a great extent.

A research study was published in the journal Advanced Functional Materials in February 2021 that illustrated the development of hydrogel-based materials that can change shape in response to psychological stimuli. This exhibit great potential as the next generation of materials for bioengineering organs, tissues, and blood vessels or other tubular structures. A constant increase in research programs for the development of innovative tissue-engineered products also supports the segment growth.

North America is Expected to Account for a Major Market Share and Maintain its Dominance During the Forecast Period.

North America, with the United States at the forefront, is anticipated to account for the major share owing to the presence of strong regulatory framework and funding bodies in the region. For instance, in July 2021, Kriya Therapeutics announced an investment of USD 100 million in a Series B funding round. The objective of the funding is to advance its platform for designing and developing next-generation gene therapies.

Moreover, with the realization of revenue profit through this space in the foreseeable future, market players are making focused attempts including expansion of product and service portfolios to enhance their market presence. For instance, in December 2021, Novartis launched T-Charge as a next-generation CAR-T platform. The platform is designed to serve as the foundation for Novartis' new investigational CAR-T cell therapies. These developments are anticipated to boost the United States market to a great extent in the future market.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Number of Clinical Trials for ATMPs

4.2.2 Growing Competition Among Market Players

4.3 Market Restraints

4.3.1 Affordability and Financial Sustainability Related Challenges

4.4 Porter's Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Therapy Type

5.1.1 Cell Therapy

5.1.2 Gene Therapy

5.1.3 CAR-T Therapy

5.1.4 Tissue Engineered Product

5.2 Geography


6.1 Company Profiles

6.1.1 Novartis AG

6.1.2 Gilead Sciences, Inc.

6.1.3 JCR Pharmaceuticals Co. Ltd

6.1.4 Bristol-Myers Squibb Company

6.1.5 F. Hoffmann-La Roche Ltd

6.1.6 Bluebird Bio Inc.

6.1.7 UniQure NV

6.1.8 Kolon TissueGene Inc.

6.1.9 Vericel Corporation

6.1.10 PHARMICELL Co. Ltd


For more information about this report visit https://www.researchandmarkets.com/r/1n3mdz


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900